THERE IS A NEED FOR NEW TOOLS IN EARLY DETECTION AND MONITORING OF CANCER
Cancer is the 2nd leading cause of death in the world. For many indications, the gold standard for diagnosis is medical imaging and/or biopsy but these methods are not always useful when symptoms are inconclusive. They are also associated with risks, high costs and inconvenience for patients. This makes them ill-suited for frequent use applications, such as tracking of disease progression or screening - where any undue risk must be avoided.
Liquid biopsies - sampling and analysis of body fluids - could provide minimally-invasive, safe and convenient means of diagnosing and monitoring cancer. If accurate enough, they might also allow for earlier detection, increasing the chance of curative treatment.
WE ARE DEVELOPING A METABOLISM-BASED LIQUID BIOPSY PLATFORM WITH A RANGE OF APPLICATIONS
Elypta is developing the first-ever metabolism-based liquid biopsy platform for early detection and closer follow-up of multiple cancer indications. The platform is inherently safe and convenient, exceptionally sensitive in studies to date and the low cost assay technology allows for broad use. Furthermore, the score output is customizable with early results suggesting correlation with the severity of disease. These features enable multiple potential applications, currently explored in the lead indication renal cell carcinoma:
Detection of early stage cancer when symptoms are inconclusive.
Earlier detection of recurring cancer by safer, more convenient and closer surveillance post-surgery.
Guide therapy by safer, more convenient and closer monitoring of response to treatment.
ELYPTA'S PLATFORM IS CURRENTLY EVALUATED IN THE CLINIC IN MULTIPLE CANCER INDICATIONS
Elypta proudly sponsors the clinical trial series AURORAX to demonstrate the clinical utility of Elypta’s platform.
Elypta is further collaborating with Chalmers University of Technology and leading academic hospitals in Sweden, Italy, Canada and the US in multiple exploratory studies. The most advanced trials are exploring clinical utility in the diagnostic work-up, surveillance for recurrence and monitoring of treatment response. In addition to renal cell carcinoma, trials are ongoing in other urologic cancers (bladder cancer and prostate cancer).
We aim to engage in more academic and industrial partnerships to validate clinical applications across indications as well as the potential use as a companion diagnostic.